Trails Edge Capital Partners, LP
Position in DSGN — Design Therapeutics, Inc.
CIK 2077247
ATLANTA, GA
Position in DSGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$9,065,418
New position
Shares Held
852,013
first reported quarter
Ownership
1.36%
of shares outstanding
% of Portfolio
2.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Trails Edge Capital Partners, LP holds $424,897,513 across 26 Biotechnology names. DSGN ranks #18 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PCVX |
Vaxcyte, Inc.
|
662,470 | $38,496,131 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
1,738,110 | $32,850,279 | |
| 3 | LBRX |
Lb Pharmaceuticals Inc
|
1,319,362 | $32,535,466 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
333,312 | $30,791,362 | |
| 5 | NRIX |
Nurix Therapeutics, Inc.
|
1,743,220 | $27,019,910 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
440,000 | $25,586,000 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
245,000 | $23,826,250 | |
| 8 | RCUS |
Arcus Biosciences, Inc.
|
1,047,935 | $22,635,396 |
All Filings in DSGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,065,418 | 852,013 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||